文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

Claudin18.2特异性CAR-T细胞治疗消化系统肿瘤:1期试验中期结果

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
PubMed 文献 · Nat Med · 2022-05-09

这项正在进行的开放标签、单臂1期临床试验中期分析了CT041(靶向CLDN18.2的CAR-T细胞)治疗经治CLDN18.2阳性消化系统肿瘤患者的安全性。37例患者接受三个剂量之一,全部发生≥3级血液学毒性,94.6%发生1-2级细胞因子释放综合征,无≥3级CRS或神经毒性、治疗相关死亡或剂量限制性毒性;总缓解率48.6%,疾病控制率73.0%,6个月缓解持续时间率44.8%;胃癌患者ORR 57.1%、DCR 75.0%,6个月总生存率81.2%。

要点

  • 全部37例接受CT041输注患者发生≥3级血液学毒性。
  • 94.6%患者发生1或2级细胞因子释放综合征,无≥3级CRS或神经毒性。
  • 总体ORR 48.6%、DCR 73.0%,胃癌患者ORR 57.1%、DCR 75.0%。

核心结论

  • 这些初步结果提示CT041在经重度治疗的CLDN18.2阳性消化系统肿瘤患者中具有令人鼓舞的疗效和可接受的安全性,尤其在胃癌患者中。

研究设计与样本

  • 正在进行的开放标签、单臂1期临床试验(NCT03874897)中期分析,评估CLDN18.2靶向CAR-T细胞(CT041)治疗经治CLDN18.2阳性消化系统肿瘤患者。
  • 共37例患者接受CT041输注,剂量为2.5×10^8、3.75×10^8或5.0×10^8个细胞之一。
  • 主要目的为CT041输注后安全性,次要目的包括疗效、药代动力学和免疫原性。

主要发现

  • 全部患者发生≥3级血液学毒性。
  • 1或2级细胞因子释放综合征发生于94.6%的患者。
  • 未报告≥3级细胞因子释放综合征或神经毒性、治疗相关死亡或剂量限制性毒性。
  • 总缓解率(ORR)为48.6%,疾病控制率(DCR)为73.0%。
  • 6个月缓解持续时间率为44.8%;胃癌患者ORR为57.1%、DCR为75.0%,6个月总生存率为81.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR T cells showed promising efficacy against gastric cancer (GC) in a preclinical study. Here we report the interim analysis results of an ongoing, open-label, single-arm, phase 1 clinical trial of CLDN18.2-targeted CAR T cells (CT041) in patients with previously treated, CLDN18.2-positive digestive system cancers ( NCT03874897 ). The primary objective was safety after CT041 infusion; secondary objectives included CT041 efficacy, pharmacokinetics and immunogenicity. We treated 37 patients with one of three CT041 doses: 2.5 × 108, 3.75 × 108 or 5.0 × 108 cells. All patients experienced a grade 3 or higher hematologic toxicity. Grade 1 or 2 cytokine release syndrome (CRS) occurred in 94.6% of patients. No grade 3 or higher CRS or neurotoxicities, treatment-related deaths or dose-limiting toxicities were reported. The overall response rate (ORR) and disease control rate (DCR) reached 48.6% and 73.0%, respectively. The 6-month duration of response rate was 44.8%. In patients with GC, the ORR and DCR reached 57.1% and 75.0%, respectively, and the 6-month overall survival rate was 81.2%. These initial results suggest that CT041 has promising efficacy with an acceptable safety profile in patients with heavily pretreated, CLDN18.2-positive digestive system cancers, particularly in those with GC.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022. PMID: 35534566. doi:10.1038/s41591-022-01800-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。